Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Laura Van 'T Veer, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentLaboratory Medicine
    Address2340 Sutter Street
    San Francisco CA 94115
    Phone415-476-6023
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of Leiden, Leiden, NetherlandsPhDMedicine, Oncogene Activation and Tumorigenesis1989
      University of Amsterdam, Amsterdam, NetherlandsMScExperimental Oncology1984
      University of Amsterdam, Amsterdam, Netherlands BSc Biology, Molecular Oncology1980
      Collapse Awards and Honors
      European Patent Office (EPO) 2015European Inventor Award 2015
      European Union Prize for Women Innovators 2014Second Prize, European Union Prize for Women Innovators
      AACC 2012AACC Outstanding Speaker Award
      Indiana University, School of Medicine2009First Annual Harry and Edith Gladstein Award,
      Breast Cancer Research Fund2007 - 2011Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
      European Society Medical Oncology (ESMO) 2007Lifetime Achievement Award for Translational Research in Breast Cancer
      EBCC52006Van der Scheuren award lecture for European Breast Cancer Research
      International Agency for Research on Cancer (IARC) , Lyon, France2005Medal of Honor
      The Irvington Institute for Medical Research, New York, USA1991 - 1994Postdoctoral Fellowship
      NWO The Netherlands Organization for Scientific Research, 's-Gravenhage, The Netherlands1989 - 1990Long-term Fellowship

      Collapse Overview 
      Collapse Overview
      Laura van ‘t Veer, PhD is Professor of Laboratory Medicine is the Program Leader of the UCSF Helen Diller Family Comprehensive Cancer Center Breast Oncology Program (BOP), Director of Applied Genomics with the UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF-Site Principal Investigator of the Athena Breast Health Network.

      Dr. van ‘t Veer is a world renowned Molecular Biologist and inventor of MammaPrint®. Her research focuses on personalized medicine, to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows clinicians to optimally assign systemic therapy for those patients in need of such treatment, and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impact patient management. Molecular genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. Her current research, involving genomics data from various types, is aimed to understand the molecular basis for early response to therapy as a surrogate for outcome prediction.

      Dr. van ‘t Veer is the Biomarker Committee Chair for the Foundation of NIH sponsored multicenter adaptive clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostic testing. She served 2010-2014 as Board member of the American Association of Cancer Research. She has over 230 peer-reviewed scientific articles and is co-inventor of 6 patents. Dr. van 't Veer received the 2007 European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer and the prestigious European Union Women Innovator Award, 2nd prize in 2014.

      Dr. van ‘t Veer received undergraduate training in biology and a master of science in molecular oncology (1984) at the University of Amsterdam in the Netherlands. She earned her PhD in Medicine for a dissertation on oncogene activation and tumorigenesis in 1989 at the University of Leiden. She then completed two postdoctoral fellowships, first at the Cancer Center of Harvard Medical School and Massachusetts General Hospital in Boston (1989-1991), followed by the Division of Molecular Carcinogenesis at The Netherlands Cancer Institute (1992-1993). She then joined The Netherlands Cancer Institute as a Molecular Biologist in the Department of Pathology. At the institute she assumed increasing responsibilities, starting with the initiation and leadership of the Departments of Molecular Pathology and Genetic Counseling, culminating with her appointment as the Head of Diagnostic Oncology, overseeing the clinical work and associated research. In 2003 she was one of the founders of the Netherlands Cancer Institute spin-off, the molecular profiling company Agendia. Concurrent to her employment at The Netherlands Cancer Institute Dr. van ‘t Veer served as the Chief Operating Officer from 2002-2007 and as the Chief Research Officer from 2007-2014 for Agenda NV, a company she founded in Amsterdam to make her scientific discoveries available to clinicians for patient use. MammaPrint® obtained the first FDA 510K ‘In Vitro Diagnostic Multigene Index Assay’ (IVDMIA) clearance in 2007, and is included in several international and national guidelines for breast cancer management.

      After a 2008-2009 appointment as Visiting Associate Professor at the UCSF Helen Diller Family Cancer Center, Dr. van ‘t Veer moved to UCSF as Professor of Laboratory Medicine in 2010 and assumed leadership of the Bay Area Breast Cancer SPORE and the BOP. In 2011 she assumed leadership of the Athena Breast Health Network at UCSF. She holds the Angela and Shu Kai Chan Endowed Chair in Cancer Research. She has established at UCSF a Laboratory for Applied Genomics that is CLIA licensed and provides a robust infrastructure and testing incubator lab for new molecular diagnostics of cancer.

      Collapse Interests
      Breast cancer, genetics, clinical trials, molecular diagnostics, applied genomics, precision medicine

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17(1):73.
        View in: PubMed
      2. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988.
        View in: PubMed
      3. van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE. Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis. PLoS One. 2015; 10(3):e0120189.
        View in: PubMed
      4. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
        View in: PubMed
      5. Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res Treat. 2014 Dec; 148(3):599-613.
        View in: PubMed
      6. Sawyers CL, van 't Veer LJ. Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. Clin Cancer Res. 2014 Oct 1; 20(19):4978-81.
        View in: PubMed
      7. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9):e107255.
        View in: PubMed
      8. van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK. Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet. 2015 May; 23(5):588-95.
        View in: PubMed
      9. Li J, Lindström LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, Michailidou K, Dennis J, Bolla MK, Wang Q, Van 't Veer LJ, Cornelissen S, Rutgers E, Southey MC, Apicella C, Dite GS, Hopper JL, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Blomqvist C, Muranen TA, Aittomäki K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Hartikainen JM, Kataja V, Chenevix-Trench G. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun. 2014; 5:4051.
        View in: PubMed
      10. Wolf DM, Lenburg ME, Yau C, Boudreau A, van 't Veer LJ. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One. 2014; 9(2):e88309.
        View in: PubMed
      11. Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EM, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2014 Mar; 16(2):190-7.
        View in: PubMed
      12. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 't Veer LJ, Hogervorst FB, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Lux MP, Ekici AB, Beckmann MW, Peto J, Dos Santos Silva I, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias JI, Benitez J, Neuhausen S, Anton-Culver H, Ziogas A, Dur CC, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Engel C, Ditsch N, Brauch H, Brüning T, Ko YD. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet. 2013 Dec 5; 93(6):1046-60.
        View in: PubMed PMC3852923
      13. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
        View in: PubMed
      14. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Imielinsk M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21.
        View in: PubMed
      15. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013 Aug 15; 133(4):929-36.
        View in: PubMed
      16. Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schürmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang X, Cox A, Brock I, Elliott G, Reed MW, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD. Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One. 2012; 7(6):e35706.
        View in: PubMed
      17. Kok M, Koornstra RH, Mook S, Hauptmann M, Fles R, Jansen MP, Berns EM, Linn SC, Van 't Veer LJ. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast. 2012 Dec; 21(6):769-78.
        View in: PubMed
      18. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
        View in: PubMed
      19. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012 Jun 21; 486(7403):400-4.
        View in: PubMed
      20. Verhagen MM, Last JI, Hogervorst FB, Smeets DF, Roeleveld N, Verheijen F, Catsman-Berrevoets CE, Wulffraat NM, Cobben JM, Hiel J, Brunt ER, Peeters EA, Gómez Garcia EB, van der Knaap MS, Lincke CR, Laan LA, Tijssen MA, van Rijn MA, Majoor-Krakauer D, Visser M, van 't Veer LJ, Kleijer WJ, van de Warrenburg BP, Warris A, de Groot IJ, de Groot R, Broeks A, Preijers F, Kremer BH, Weemaes CM, Taylor MA, van Deuren M, Willemsen MA. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. 2012 Mar; 33(3):561-71.
        View in: PubMed
      21. Hilbers FS, Boekel NB, van den Broek AJ, van Hien R, Cornelissen S, Aleman BM, van 't Veer LJ, van Leeuwen FE, Schmidt MK. Genetic variants in TGFß-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol. 2012 Jan; 102(1):115-21.
        View in: PubMed
      22. Stevens KN, Garcia-Closas M, Fredericksen Z, Kosel M, Pankratz VS, Hopper JL, Dite GS, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 't Veer LJ, Tollenaar RA, Fasching PA, Beckmann MW, Hein A, Ekici AB, Johnson N, Peto J, dos Santos Silva I, Gibson L, Sawyer E, Tomlinson I, Kerin MJ, Chanock S, Lissowska J, Hunter DJ, Hoover RN, Thomas GD, Milne RL, Arias Pérez JI, González-Neira A, Benítez J, Burwinkel B, Meindl A, Schmutzler RK, Bartrar CR, Hamann U, Ko YD, Brüning T, Chang-Claude J, Hein R, Wang-Gohrke S, Dörk T, Schürmann P, Bremer M, Hillemanns P, Bogdanova N, Zalutsky JV, Rogov YI, Antonenkova N, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen J, Chenevix-Trench G, Chen X, Peterlongo P, Bonanni B, Bernard L, Manoukian S, Wang X, Cerhan J, Vachon CM, Olson J, Giles GG, Baglietto L, McLean CA, Severi G, John EM, Miron A, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight JA, Glendon G, Mulligan AM, Cox A, Brock IW, Elliott G, Cross SS, Pharoah PP, Dunning AM, Pooley KA, Humphreys MK, Wang J, Kang D, Yoo KY, Noh DY, Sangrajrang S, Gabrieau V, Brennan P, McKay J, Anton-Culver H, Ziogas A, Couch FJ, Easton DF. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer. 2011 Dec 6; 105(12):1934-9.
        View in: PubMed
      23. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34.
        View in: PubMed
      24. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011 Aug; 12(8):1137-46.
        View in: PubMed
      25. Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Pérez JI, Benítez J, Dörk T, Schürmann P, Karstens JH, Hillemanns P, Cox A, Brock IW, Elliot G, Cross SS, Seal S, Turnbull C, Renwick A, Rahman N, Shen CY, Yu JC, Huang CS, Hou MF, Nordestgaard BG, Bojesen SE, Lanng C, Grenaker Alnæs G, Kristensen V, Børrensen-Dale AL, Hopper JL, Dite GS, Apicella C, Southey MC, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Chang-Claude J, Wang-Gohrke S, Radice P, Peterlongo P, Manoukian S, Barile M, Giles GG, Baglietto L, John EM, Miron A, Chanock SJ, Lissowska J, Sherman ME, Figueroa JD, Bogdanova NV, Antonenkova NN, Zalutsky IV, Rogov YI, Fasching PA, Bayer CM, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Meindl A, Heil J, Bartram CR, Schmutzler RK, Thomas GD, Hoover RN, Fletcher O, Gibson LJ, dos Santos Silva I, Peto J, Nickels S, Flesch-Janys D, Anton-Culver H, Ziogas A, Sawyer E, Tomlinson I, Kerin M, Miller N, Schmidt MK, Broeks A, Van 't Veer LJ, Tollenaar RA, Pharoah PD, Dunning AM, Pooley KA, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Jakubowska A, Lubinski J, Jaworska K, Durda K, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Kraft P, Lindstrom S, Chen X, Beesley J, Hamann U, Harth V, Justenhoven C. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2222-31.
        View in: PubMed
      26. Bruin SC, He Y, Mikolajewska-Hanclich I, Liefers GJ, Klijn C, Vincent A, Verwaal VJ, de Groot KA, Morreau H, van Velthuysen ML, Tollenaar RA, van 't Veer LJ. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer. 2011 Jul 12; 105(2):281-7.
        View in: PubMed
      27. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Ørsted DD, Kaur-Knudsen D, Milne RL, Pérez JI, Zamora P, Rodríguez PM, Benítez J, Brauch H, Justenhoven C, Ko YD. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011 Aug 15; 20(16):3289-303.
        View in: PubMed
      28. Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst. 2011 Apr 6; 103(7):585-97.
        View in: PubMed
      29. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Pérez JI, Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Górski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collée M, Wang-Gohrke S, Pylkäs K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Ørsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011 Feb 2; 103(3):250-63.
        View in: PubMed
      30. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer. 2010 Dec 7; 103(12):1788-93.
        View in: PubMed
      31. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010 Jun; 47(6):421-8.
        View in: PubMed
      32. Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010 Apr; 120(3):655-61.
        View in: PubMed
      33. Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, van Leeuwen FE, Van 't Veer LJ. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys. 2010 Feb 1; 76(2):540-7.
        View in: PubMed
      34. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009 Dec 24; 462(7276):1005-10.
        View in: PubMed
      35. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010 Apr; 21(4):717-22.
        View in: PubMed
      36. Linn SC, Van 't Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009 Sep; 45 Suppl 1:11-26.
        View in: PubMed
      37. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008; 10(6):R93.
        View in: PubMed
      38. Molloy T, van 't Veer LJ. Recent advances in metastasis research. Curr Opin Genet Dev. 2008 Feb; 18(1):35-41.
        View in: PubMed
      39. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008 Jan; 107(2):243-8.
        View in: PubMed
      40. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9(2):R26.
        View in: PubMed
      41. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006 Oct; 3(10):540-51.
        View in: PubMed
      42. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 1; 23(31):7804-10.
        View in: PubMed
      43. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005 Aug; 5(8):591-602.
        View in: PubMed
      44. van 't Veer L. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview. JAMA. 2004 Aug 11; 292(6):675.
        View in: PubMed
      45. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004 Apr; 84(3):225-33.
        View in: PubMed
      46. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd. 2004 Mar 20; 148(12):564-8.
        View in: PubMed
      47. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
        View in: PubMed
      48. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004 Feb 1; 64(3):840-3.
        View in: PubMed
      49. Weigelt B, Bosma AJ, van 't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol. 2003 Dec; 129(12):735-6.
        View in: PubMed
      50. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003 Apr 7; 88(7):1091-4.
        View in: PubMed
      51. Broeks A, van 't Veer LJ, Ottenheim C, Hiel JA, Kleijer WJ, Weemaes C. [From gene to disease; ataxia telangiectasia]. Ned Tijdschr Geneeskd. 2003 Mar 1; 147(9):386-9.
        View in: PubMed
      52. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003; 5(1):57-8.
        View in: PubMed
      53. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res. 2002 Jun; 8(6):1871-7.
        View in: PubMed
      54. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan 31; 415(6871):530-6.
        View in: PubMed
      55. Van 't Veer LJ, De Jong D. The microarray way to tailored cancer treatment. Nat Med. 2002 Jan; 8(1):13-4.
        View in: PubMed
      56. van Dijk MA, Hart AA, van 't Veer LJ. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res. 2000 Feb 1; 60(3):530-3.
        View in: PubMed
      57. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000 Feb; 66(2):494-500.
        View in: PubMed
      58. Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am. 2000 Jan-Feb; 6(1):2-10.
        View in: PubMed
      59. Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar; 79(9-10):1475-8.
        View in: PubMed
      60. Kersten MJ, Surachno S, Koopman MG, van 't Veer LJ, Pals ST, van Oers MH. [Epstein-Barr virus in a donor kidney as a cause of non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):360-4.
        View in: PubMed
      61. Taal BG, van Loon HJ, Kahn N, de Jong D, Vasen HF, van 't Veer LJ. [The role of genetic factors in the development of gastric cancer]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):342-6.
        View in: PubMed
      62. Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M. Towards prediction and modulation of treatment response. Radiother Oncol. 1999 Jan; 50(1):1-11.
        View in: PubMed
      63. Lambrechts AC, van 't Veer LJ, Rodenhuis S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol. 1998 Dec; 9(12):1269-76.
        View in: PubMed
      64. Dallinga JW, Pachen DM, Wijnhoven SW, Breedijk A, van 't Veer L, Wigbout G, van Zandwijk N, Maas LM, van Agen E, Kleinjans JC, van Schooten FJ. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):571-7.
        View in: PubMed
      65. Godschalk RW, Maas LM, Van Zandwijk N, van 't Veer LJ, Breedijk A, Borm PJ, Verhaert J, Kleinjans JC, van Schooten FJ. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis. 1998 May; 19(5):819-25.
        View in: PubMed
      66. Ceha HM, Balm AJ, de Jong D, van 't Veer LJ. Multiple malignancies in a patient with bilateral retinoblastoma. J Laryngol Otol. 1998 Feb; 112(2):189-92.
        View in: PubMed
      67. Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population. Hum Mutat. 1998; 12(5):330-7.
        View in: PubMed
      68. Van Zandwijk N, Van 't Veer LJ. The role of prognostic factors and oncogenes in the detection and management of non-small-cell lung cancer. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):55-9.
        View in: PubMed
      69. de Lange MS, Top B, Lambrechts C, Maas RA, Peterse HL, Mooi WJ, van 't Veer LJ, Rodenhuis S. A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. Diagn Mol Pathol. 1997 Dec; 6(6):353-60.
        View in: PubMed
      70. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van 't Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov; 17(3):341-5.
        View in: PubMed
      71. van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res. 1997 Aug 15; 57(16):3478-85.
        View in: PubMed
      72. de Jong D, Richel DJ, Schenkeveld C, Boerrigter L, van 't Veer LJ. Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. Diagn Mol Pathol. 1997 Aug; 6(4):244-8.
        View in: PubMed
      73. Weeda G, Rossignol M, Fraser RA, Winkler GS, Vermeulen W, van 't Veer LJ, Ma L, Hoeijmakers JH, Egly JM. The XPB subunit of repair/transcription factor TFIIH directly interacts with SUG1, a subunit of the 26S proteasome and putative transcription factor. Nucleic Acids Res. 1997 Jun 15; 25(12):2274-83.
        View in: PubMed
      74. Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev. 1997 Jan 15; 11(2):226-40.
        View in: PubMed
      75. Wolthuis RM, Bauer B, van 't Veer LJ, de Vries-Smits AM, Cool RH, Spaargaren M, Wittinghofer A, Burgering BM, Bos JL. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene. 1996 Jul 18; 13(2):353-62.
        View in: PubMed
      76. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol. 1995 Jun; 15(6):3082-9.
        View in: PubMed PMC230539
      77. van 't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, Schrier PI. Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene. 1993 Oct; 8(10):2673-81.
        View in: PubMed
      78. Hateboer G, Timmers HT, Rustgi AK, Billaud M, van 't Veer LJ, Bernards R. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8489-93.
        View in: PubMed
      79. van 't Veer LJ, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J. 1993 Jan; 12(1):195-200.
        View in: PubMed
      80. van 't Veer LJ, Lutz PM, Isselbacher KJ, Bernards R. Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1992 Oct 1; 89(19):8971-5.
        View in: PubMed
      81. Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van 't Veer LJ, Krüse-Wolters KM. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol. 1991 Feb; 2(1):73-83.
        View in: PubMed
      82. Rustgi AK, Van 't Veer LJ, Bernards R. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8707-10.
        View in: PubMed
      83. van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul; 9(7):3114-6.
        View in: PubMed
      84. Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988 Jun 15; 48(12):3355-9.
        View in: PubMed
      85. van 't Veer LJ, Hermens R, van den Berg-Bakker LA, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ, Schrier PI. ras oncogene activation in human ovarian carcinoma. Oncogene. 1988 Feb; 2(2):157-65.
        View in: PubMed
      86. van 't Veer LJ, van den Berg-Bakker LA, Hermens RP, Deprez RL, Schrier PI. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay. Oncogene Res. 1988; 3(3):247-54.
        View in: PubMed
      87. van 't Veer LJ, van Kessel AG, van Heerikhuizen H, van Ooyen A, Nusse R. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis. Mol Cell Biol. 1984 Nov; 4(11):2532-4.
        View in: PubMed
      Laura's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP